 | Up a level |
Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Driessen, Christoph; Duchosal, Michel A; Heim, Dominik; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Schmidt, Adrian; Taverna, Christian; Zander, Thilo; Renner, Christoph (2019). Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 2019(149), pp. 1-8. EMH Media 10.4414/smw.2019.20031
Voegeli, Michèle; Rondeau, Stephanie; Berardi Vilei, Simona; Lerch, Erika; Wannesson, Luciano; Pabst, Thomas; Rentschler, Jochen; Bargetzi, Mario; Jost, Lorenz; Ketterer, Nicolas; Bischof Delaloye, Angelika; Ghielmini, Michele (2017). Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). Hematological oncology, 35(4), pp. 576-583. Wiley 10.1002/hon.2348
Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Duchosal, Michel A; Heim, Dominik; Hess, Urs; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Taverna, Christian; Zander, Thilo; Renner, Christoph (2015). Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 145, w14100. EMH Schweizerischer Ärzteverlag 10.4414/smw.2015.14100
Ghielmini, Michele; Hsu Schmitz, Shu-Fang; Martinelli, Giovanni; Peccatori, F; Hess, Urs; Fey, Martin; Zucca, Emanuele; Stahel, Rolf; Ketterer, Nicolas; Cerny, Thomas (2009). Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. Journal of clinical oncology, 27(15), p. 8512. American Society of Clinical Oncology
